An oral, brain penetrant EGFR mutant inhibitor with exquisite selectivity, a drug that was originally developed from a brain cholesterol metabolite, and a muscarinic antagonist and β2 agonist that was developed using soft drug design are some examples of this month's MOTM.
In the slide deck, you'll also find a drug utilizing an N-oxide motif and a drug optimized to overcome aldehyde oxidase metabolism.
Check out the ten molecule minireviews in the slide deck which covers:
- Where are all of the Molecules of the Month in clinical development?
- What's known about differentiation from previous molecules?
- Where did the starting points come from?
- Industry context, mechanism of action details, and more…
A slide deck with more details about each molecule is available.Upgrade Membership to Download Slide Deck